NeuBase Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation (Tables)

Stock-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2023

Stock-Based Compensation

Schedule of stock-based compensation expense


		Three Months Ended June 30,						Six Months Ended June 30,
		2023			2022			2023			2022
General and administrative		$	209,522		$	507,435		$	481,732		$	1,062,096
Research and development			35,490			133,611			79,969			531,778
Total		$	245,012		$	641,046		$	561,701		$	1,593,874

Schedule of stock options issued and outstanding


					Weighted-		Weighted-
					Average		Average		Total
					Exercise		Remaining		Aggregate
					Price Per		Contractual		Intrinsic
		Stock Options			Share		Life (in years)		Value
Outstanding at December 31, 2022		365,287		$	53.27
Granted		1,875			4.34
Exercised		(32,750)			0.02
Forfeited		(19,740)			94.82
Outstanding at June 30, 2023		314,672			55.91		6.0		$	172,296
Exercisable as of June 30, 2023		240,712		$	58.15		5.2		$	172,296

Schedule of key assumptions used to estimate the fair value of the stock options granted


		Six Months Ended June 30,
		2023		2022
Expected term of options (years)		5.4 - 6.1		5.3 - 6.1
Expected common stock price volatility		82.3% - 85.2%		73.7% - 77.2%
Risk-free interest rate		3.5% - 4.0%		1.4% - 3.1%
Expected dividend yield		—		—

Schedule of changes in the outstanding restricted stock


					Weighted-
					Average Grant
		Restricted Stock			Date Fair Value
		Units			Price
Unvested as of December 31, 2022			—		$	—
Granted			19,823			4.00
Forfeited			—			—
Unvested as of June 30, 2023			19,823			4.00
Total unrecognized expense remaining		$	65,602
Weighted-average years expected to be recognized over			1.9